Osmotica Pharmaceutical Corp. received notice of final approval for its Venlafaxine Hydrochloride Extended-release 37.5 mg, 75 mg, 150 mg and 225 mg tablets NDA from FDA for major depressive disorder and social anxiety disorder. The Osmotica product provides a controlled release tablet form of venlafaxine HCl including a previously unavailable 225 mg dosage strength.
Popularity: unranked [?]
Related posts:
- Efexor (Venlafaxine) Questions And Answers, MHRA, UK
- Actavis Receives Approval Of Generic Wellbutrin XL(R) 300mg In The United States
- Par Pharmaceutical Receives Final Approval To Market Tranylcypromine Sulfate Tablets
- Mylan Announces Tentative Approval For Venlafaxine Hydrochloride Tablets
- Venlafaxine Extended Release Effective For Patients With Major Depression
Comments
No Responses to “Osmotica Pharmaceutical Receives FDA Approval To Market Novel Forms Of Extended Release Venlafaxine HCl”